Valuation : Icure Pharmaceutical Incorporation

Market Cap 78.48B 58.27M 50.14M 47.18M 43.1M 80.62M 5.5B 80.84M 557M 216M 2.82B 219M 214M 9.09B P/E 2024
64.8x
P/E 2025 -2.42x
Enterprise Value 95.12B 70.63M 60.78M 57.18M 52.24M 97.72M 6.67B 97.99M 676M 262M 3.42B 265M 259M 11.02B EV / Sales 2024
1.24x
EV / Sales 2025 1.17x
Free-Float
84.42%
Yield 2024 *
-
Yield 2025 -
08-27 Icure Pharmaceutical Incorporation announced that it has received KRW 24.999999266 billion in funding from Solum Cosmetic Co.,Ltd, Deep Dive Partners, Sinsin Pharmaceutical Co., Ltd CI
08-14 Icure Pharmaceutical Incorporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
05-15 Icure Pharmaceutical Incorporation Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
03-30 Icure Pharmaceutical Incorporation Reports Earnings Results for the Full Year Ended December 31, 2025 CI
11-16 Huons Natural Co,Ltd. acquired Bio Rosette Co.,Ltd. CI
11-14 Icure Pharmaceutical Incorporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
25-08-14 Icure Pharmaceutical Incorporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 CI
25-05-15 Icure Pharmaceutical Incorporation Reports Earnings Results for the First Quarter Ended March 31, 2025 CI
25-03-21 Icure Pharmaceutical Incorporation Reports Earnings Results for the Full Year Ended December 31, 2024 CI
24-12-26 Icure Pharmaceutical Incorporation announced that it has received KRW 9 billion in funding from Sangsangin Plus Savings Bank Co.,Ltd., Sangsangin Savings Bank CI
24-12-23 Icure Pharmaceutical Incorporation announced that it expects to receive KRW 9 billion in funding from Sangsangin Plus Savings Bank Co.,Ltd., Sangsangin Savings Bank CI
24-11-14 Icure Pharmaceutical Incorporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 CI
24-08-14 Icure Pharmaceutical Incorporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 CI
1 day-0.47%
1 week-3.23%
Current month-3.23%
1 month-3.23%
3 months-3.23%
6 months-3.23%
Current year-3.23%
1 week 1,778
Extreme 1778
3,300
1 month 1,778
Extreme 1778
3,300
Current year 1,778
Extreme 1778
3,300
1 year 1,778
Extreme 1778
3,300
3 years 1,399
Extreme 1399
3,490
5 years 1,399
Extreme 1399
20,520.83
10 years 1,399
Extreme 1399
28,645.83
Manager TitleAgeSince
Chief Executive Officer 62 2022-03-30
Chief Executive Officer 66 -
Corporate Officer/Principal 52 2022-03-30
Director TitleAgeSince
Chairman 66 -
Director/Board Member 77 2022-03-30
Director/Board Member 52 2022-03-30
Date Insider Type Main position Quantity % Market Cap. Importance
5/20/24 Buy

Chief Executive Officer

3,637 0.0097%
Change 5-day change 1-year change 3-year change Capi.($)
-0.47%-3.23%-3.23%-17.32% 58.27M
-0.88%-2.15%+58.05%+105.26% 1,024B
-1.15%+2.68%+54.25%+74.19% 663B
-1.44%+0.38%+20.65%+76.13% 453B
-0.55%+0.45%+31.21%+38.09% 352B
-2.52%+2.09%+22.99%+41.98% 304B
+1.64%+1.94%+1.87%+12.66% 252B
-1.55%+1.11%+54.15%+75.59% 236B
-0.01%+2.17%-13.89%-55.83% 206B
-0.15%+3.65%+31.24%+103.39% 187B
Average -0.70%+1.93%+25.73%+45.41% 367.84B
Weighted average by Cap. -0.88%+0.62%+37.81%+67.06%

Financials

2024 2025
Net sales 69.21B 51.39M 44.22M 41.61M 38.01M 71.1M 4.85B 71.29M 492M 191M 2.49B 193M 189M 8.02B 83.38B 61.92M 53.28M 50.13M 45.79M 85.66M 5.85B 85.9M 592M 230M 3B 233M 227M 9.66B
Net income 1.2B 889K 765K 720K 658K 1.23M 83.96M 1.23M 8.51M 3.3M 43.08M 3.34M 3.27M 139M -33.6B -24.95M -21.47M -20.2M -18.45M -34.52M -2.36B -34.61M -239M -92.62M -1.21B -93.69M -91.64M -3.89B
Net Debt 18B 13.37M 11.5M 10.82M 9.89M 18.5M 1.26B 18.55M 128M 49.63M 648M 50.2M 49.1M 2.09B 16.64B 12.36M 10.64M 10.01M 9.14M 17.1M 1.17B 17.15M 118M 45.88M 599M 46.41M 45.4M 1.93B
Logo Icure Pharmaceutical Incorporation
Icure Pharmaceutical Incorporation is a Korea-based company mainly engaged in the production and sale of cosmetics. Along with subsidiaries, the Company operates its business through two segments. The Cosmetic segment is involved in the manufacturing and sale of cosmetics including basic cosmetics, mask packs, and patches. In addition, it is also engaged in the production and sale of body, hair care products and fragrances. The cosmetics are sold under the names of Botalinum, Mediheal N.M.F, Meditime, among others. The Pharmaceutical segment is engaged in the manufacturing and sale of over the counter (OTC) drugs, ethical the counter (ETC) drugs, as well as quasi drugs. The OTC drugs include anti-inflammatory analgesics and dementia treatments. The Company distributes its products within the domestic market and to overseas markets.
Employees
232
Date Price Change Volume
26-09-04 ₩2,100.00 -0.47% 1,833,113
  1. Stock Market
  2. Stocks
  3. A175250 Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!